This resistance was reverted upon co-treatment with Erastin, which reduced CSE activity and consequently increased Temozolomide cytotoxicity, highlighting the possible involvement of CSE in chemotherapeutic resistance in brain tumors [118]. Here, CTH is linked to brain neoplasm.